Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic capecitabine after standard therapy for locoregionally advanced head and neck squamous cell carcinoma
ChiCTR2100052130Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Started Oct 2021; status: recruiting.
02
Drugs
capecitabine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2100052130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052130.